Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eight-week multicenter double-blind placebo-controlled Phase 3 study of saredutant 100 mg in major depressive disorder
2004-002327-41Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Saredutant 100 mg with Placebo (2 arms). Primary endpoint: Change from baseline to Day 56 in 17-item Hamilton Depression Rating Scale total score. Started Nov 2004; status: completed.
02
Drugs
saredutant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2004-002327-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002327-41.